Become A Wiser, More Profitable Investor

Adaptive phase I-II clinical trial designs identifying optimal biological doses for targeted agents and immunotherapies

science

Targeted agents and immunotherapies have revolutionized cancer treatment, offering promising options for various cancer types. Unlike traditional therapies the principle of "more is better" is not always applicable to these new therapies due to their unique biomedical mechanisms. As a result, various phase I-II clinical trial designs have been proposed to identify the optimal biological dose that maximizes the therapeutic effect of targeted therapies and immunotherapies by jointly monitoring...

NCBI     Jan 11, 2024